Core Insights - Idorsia Ltd's novel dual endothelin receptor antagonist, TRYVIO™ (aprocitentan), has been included in the updated clinical practice guidelines for managing systemic hypertension by the American College of Cardiology (ACC) and the American Heart Association (AHA) [1][9] - TRYVIO is recognized as a treatment option for adults with difficult-to-control hypertension, including resistant hypertension, marking it as the first systemic hypertension treatment to target a new pathway in over 30 years [1][9] Company Overview - Idorsia is focused on discovering and developing innovative medicines to improve patient outcomes, with a commitment to addressing unmet medical needs in hypertension management [4][17] - The company has a strong scientific core and aims to evolve into a leading biopharmaceutical company, leveraging its in-house capabilities and partnerships [17][18] Product Information - TRYVIO is indicated for the treatment of hypertension in combination with other antihypertensive drugs, with a recommended dosage of 12.5 mg orally once daily [3][10] - The drug is particularly suitable for patients with hypertension and chronic kidney disease (CKD), as it can be used in patients with an estimated glomerular filtration rate (eGFR) as low as 15 mL/min [3][10] Clinical Evidence - Clinical evidence supports that TRYVIO effectively lowers blood pressure and reduces the risk of cardiovascular events, including strokes and myocardial infarctions [3][9] - Post-hoc analyses presented at the AHA Hypertension Scientific Sessions indicate that aprocitentan provides fast blood pressure control and significant reductions in urinary albumin-to-creatinine ratio (UACR) [6][5] Industry Context - Hypertension is a major global health issue, affecting an estimated 50% of adults in the US, with half of those patients not well controlled despite medication [2][9] - The updated guidelines reflect a shift towards evidence-based practices in managing high blood pressure, emphasizing the importance of new treatment options like TRYVIO [8][9] Recognition - TRYVIO has been nominated for the 2025 Prix Galien USA Awards in the category of "Best Pharmaceutical Product," highlighting its innovative approach in hypertension treatment [7]

Core Viewpoint - Idorsia Ltd's TRYVIO™ (aprocitentan) has been nominated for the "Best Pharmaceutical Product" category in the 2025 Prix Galien USA awards, highlighting its innovative approach to treating systemic hypertension [1][5]. Company Overview - Idorsia is focused on developing transformative medicines and aims to evolve into a leading biopharmaceutical company with a strong scientific foundation [8][9]. - The company is headquartered near Basel, Switzerland, and has a dedicated team covering all disciplines from research to commercialization [9]. Product Information - TRYVIO™ is the first systemic hypertension treatment targeting a new pathway in over 30 years, functioning as a dual endothelin receptor antagonist (ERA) [3][7]. - It is indicated for use in combination with other antihypertensive drugs to lower blood pressure in adult patients inadequately controlled on existing therapies [3][7]. - TRYVIO™ has shown consistent blood pressure-lowering effects across various patient subgroups, including those with difficult-to-treat hypertension [4]. Health Impact - Hypertension affects an estimated 50% of adults in the US, with half of those patients not well controlled despite medication, leading to increased risks of cardiovascular events [4]. - The treatment of hypertension is critical as it is the number one modifiable risk factor for early morbidity and mortality [4]. Award Significance - The Prix Galien Award is recognized globally as a prestigious honor in biopharmaceutical research, akin to the Nobel Prize, celebrating innovations that improve human health [5].